Submitted by Anonymous (not verified) on 27 May 2026 - 13:24
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 17, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 17, Status: Authorised